2-[4-(4'-methylsulfonylamino-1,1'-biphenylsulfonyl)piperazin-1-yl]-1,3-thiazole-5-carboxylic acid hydroxyamide | 1026051-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(4'-methylsulfonylamino-1,1'-biphenylsulfonyl)piperazin-1-yl]-1,3-thiazole-5-carboxylic acid hydroxyamide
• 英文别名: N-hydroxy-2-[4-[2-[4-(methanesulfonamido)phenyl]phenyl]sulfonylpiperazin-1-yl]-1,3-thiazole-5-carboxamide
• CAS: 1026051-75-1
• 化学式: C₂₁H₂₃N₅O₆S₃
• 分子量: 537.642
• InChiKey: QTHOMTMYOMNNAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  194
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• Inhibitors of histone deacetylase
  申请人：Anandan K. Sampath

  公开号：US20050250784A1

  公开（公告）日：2005-11-10

  Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC.

  揭示了抑制组蛋白去乙酰化酶（HDAC）酶活性的化合物。还揭示了包含这些化合物的药物组合物，以及治疗由HDAC至少部分介导的疾病的方法，特别是增殖性疾病。
• MSMB-gene based diagnosis, staging and prognosis of prostate cancer
  申请人：Beke Lijs

  公开号：US20090203010A1

  公开（公告）日：2009-08-13

  This invention relates generally to a method of diagnosis for distinguishing between a benign prostate hyperplasia and a prostate cancer and between a hormone-sensitive and a hormone-refractory prostate cancer condition and specifically to identification of a hypermethylated (on CpG and non-CpG dinucleotides) CpG island in the beta-microseminoprotein (MSMB) regulatory regions surrounding the transcriptional start site of the MSMB gene as a diagnostic indicator of prostate cancer (PrCa) and for distinguishing androgen-refractory from androgen-sensitive prostate cancer.